Notice of AGM

Vectura Group plc (the "Company") (LSE: VEC)

Notice of Annual General Meeting and General Meeting

Chippenham, UK, 21 August 2015: The Company today gives notice of the following:

- The Annual General Meeting ("AGM") for 2015 will be held on Thursday, 24 September 2015 at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH, commencing at 12.00 noon.

- A General Meeting ("GM") will also be held on Thursday, 24 September 2015 at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH, commencing at 1.00pm.

Copies of the Notice of AGM and GM and respective Forms of Proxy have been sent to shareholders today. The Notice of AGM and GM are also available on the Company's website at: www.vectura.com.

In accordance with the Listing Rule 9.6.1, copies of the Notice of AGM and GM have been submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM.

Enquiries

Vectura Group plc

Andrew J Oakley

Chief Financial Officer and Company Secretary

One Prospect West

Chippenham

Wiltshire

SN14 6FH

Tel: +44 (0)1249 667700

www.vectura.com

Notes for Editors:

About Vectura

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth $44 billion worldwide.1

Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.

Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

For further information, please visit Vectura's website at www.vectura.com.

1 Decision Resources 2014